Taro Pharmaceutical Industries Ltd. (TARO) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a one year consensus target price of $120.00 for the company and are forecasting that the company will post $2.15 EPS for the current quarter, according to Zacks. Zacks has also assigned Taro Pharmaceutical Industries an industry rank of 79 out of 257 based on the ratings given to its competitors.

Several analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $120.00 price target on shares of Taro Pharmaceutical Industries in a research note on Friday, August 10th. Zacks Investment Research downgraded shares of Taro Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 16th. Finally, ValuEngine raised shares of Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Wednesday.

Shares of Taro Pharmaceutical Industries stock traded up $3.06 on Friday, hitting $107.92. 115,257 shares of the company traded hands, compared to its average volume of 40,041. Taro Pharmaceutical Industries has a 52 week low of $93.01 and a 52 week high of $121.23. The company has a market capitalization of $4.25 billion, a PE ratio of 17.46 and a beta of 0.36.

Taro Pharmaceutical Industries (NYSE:TARO) last posted its quarterly earnings results on Monday, November 5th. The company reported $1.60 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.96 by ($0.36). Taro Pharmaceutical Industries had a net margin of 36.33% and a return on equity of 11.99%. The company had revenue of $158.97 million for the quarter, compared to the consensus estimate of $167.40 million. As a group, research analysts expect that Taro Pharmaceutical Industries will post 7.65 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of TARO. Highstreet Asset Management Inc. raised its stake in Taro Pharmaceutical Industries by 11.0% in the third quarter. Highstreet Asset Management Inc. now owns 5,943 shares of the company’s stock worth $584,000 after buying an additional 588 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Taro Pharmaceutical Industries by 5.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 13,425 shares of the company’s stock worth $1,320,000 after buying an additional 675 shares in the last quarter. Hudson Capital Management LLC raised its stake in Taro Pharmaceutical Industries by 7.4% in the third quarter. Hudson Capital Management LLC now owns 9,915 shares of the company’s stock worth $975,000 after buying an additional 687 shares in the last quarter. Dynamic Technology Lab Private Ltd raised its stake in Taro Pharmaceutical Industries by 31.1% in the second quarter. Dynamic Technology Lab Private Ltd now owns 3,230 shares of the company’s stock worth $374,000 after buying an additional 766 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in Taro Pharmaceutical Industries by 3.6% in the third quarter. Russell Investments Group Ltd. now owns 24,737 shares of the company’s stock worth $2,432,000 after buying an additional 871 shares in the last quarter. 10.95% of the stock is owned by hedge funds and other institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

See Also: What is Depreciation?

Get a free copy of the Zacks research report on Taro Pharmaceutical Industries (TARO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit